Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening
Evaluation of the Clinical Performance of Lumetry for paCO2 Assessment and COPD Screening
The purpose of this clinical study is to evaluate how well the lumetry device performs in two areas: estimating the level of carbon dioxide in the arterial blood (paCO2) and screening for chronic obstructive pulmonary disease (COPD).
lumetry is a small handheld device that analyzes exhaled breath. Participants breathe normally into the device for 60 seconds. No forced or maximal breathing maneuvers are required for the lumetry measurement.
Today, the carbon dioxide level in the blood is usually measured with a blood gas analysis, which requires a blood sample. COPD is usually diagnosed with spirometry, a lung function test that requires maximal breathing effort and trained staff.
In this study, adults with COPD of different severity and adults without known lung disease each attend a single study visit. All participants perform one lumetry breath measurement and a standard lung function test (forced spirometry). Participants with COPD also give a small capillary blood sample from the earlobe for blood gas analysis, and some of them additionally have their carbon dioxide level measured through the skin (transcutaneous measurement). By comparing the lumetry results with these established methods, the study assesses how accurately the device estimates the carbon dioxide level in the blood. By comparing the lumetry COPD screening result with spirometry and the confirmed clinical diagnosis, the study assesses how reliably the device distinguishes between people with and without COPD.
The study is conducted at one hospital in Vienna, Austria, and will include 300 participants.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Ruth Masih, MSc Biotechnology
- 电话号码:+4366488262391
- 邮箱:ruth.masih@lumetry.at
研究联系人备份
- 姓名:Nejla Hidic, BSc Biomedical Engineering
- 电话号码:+4366488262391
- 邮箱:nejla.hidic@lumetry.at
学习地点
-
-
State of Vienna
-
Vienna、State of Vienna、奥地利、A-1210
- Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine
-
接触:
- Arschang Valipour, Prim. Priv. -Doz. Dr.
- 邮箱:arschang.valipour@gesundheitsverbund.at
-
接触:
- Theresa Klemm, Medical Doctor
- 邮箱:theresa.klemm@gesundheitsverbund.at
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written informed consent
- Age between 18 and 90 years
- Diagnosed chronic obstructive pulmonary disease (COPD), stages GOLD I to IV, or no known lung function pathologies
- Able to sit upright for the duration of the procedure without exhaustion
- Women of childbearing potential: not breastfeeding and either a negative pregnancy test prior to the start of the investigation or use of a reliable method of contraception (intrauterine device or oral contraceptive pill) throughout the investigation. Women of childbearing potential are defined as women who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal (at least 12 months of amenorrhea in a woman over the age of 50 in the absence of other biological or physiological causes).
Exclusion Criteria:
- Considered by the investigator to be inappropriate for inclusion or unlikely to comply with the requirements of the study
- Lung disease other than COPD (e.g., asthma); participants with asthma-COPD overlap may be included
- Previously documented chronic heart failure with an ejection fraction below 40%
- Mental or physical inability to comply with time schedules and study procedures
- Current participation in a clinical study that may affect breathing behaviour (medicinal product or medical device), or participation within 30 days prior to screening
- Prior participation in this clinical investigation
- Possible or confirmed pregnancy, or breastfeeding
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Participants With and Without COPD
Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring. |
Handheld capnography and spirometry device that estimates the arterial partial pressure of carbon dioxide (paCO2) and provides a COPD screening result from a single 60-second measurement of normal resting breathing. The device also provides the end-tidal carbon dioxide value (petCO2), which serves as comparator for the paCO2 estimate. Capillary blood sample from the arterialized earlobe, collected immediately after the lumetry measurement. Reference standard for paCO2. Performed in participants with COPD only. Non-invasive measurement of carbon dioxide through the skin (tcPCO2), recorded as close in time as possible to the lumetry measurement and blood sampling. Comparator for paCO2 estimation. Performed in a subgroup of 50 participants with COPD. Standard lung function test performed at the end of the study visit in all participants. Together with the documented clinical diagnosis, reference standard for the COPD screening result. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)
大体时间:Day 1 (single study visit)
|
In participants with chronic obstructive pulmonary disease (COPD), the carbon dioxide level in the arterial blood (paCO2) estimated by lumetry is compared with the value measured in a capillary blood sample (blood gas analysis, reference standard). The average size of the difference, regardless of direction (mean absolute deviation), is calculated for lumetry and for the standard breath-based value (end-tidal carbon dioxide, petCO2). The outcome is the MAD of petCO2 minus the MAD of lumetry, so a positive value means lumetry is closer to the blood gas value. |
Day 1 (single study visit)
|
|
Sensitivity of the lumetry COPD Screening Result
大体时间:Day 1 (single study visit)
|
Percentage of participants with COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as positive by the lumetry COPD screening result. |
Day 1 (single study visit)
|
|
Specificity of the lumetry COPD Screening Result
大体时间:Day 1 (single study visit)
|
Percentage of participants without COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as negative by the lumetry COPD screening result. |
Day 1 (single study visit)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2
大体时间:Day 1 (single study visit)
|
In participants with chronic obstructive pulmonary disease (COPD), the difference between the lumetry-estimated arterial carbon dioxide level (paCO2) and the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for each participant. The outcome is the standard deviation of these differences, describing the precision of the lumetry estimate. Unit: millimeters of mercury (mmHg). |
Day 1 (single study visit)
|
|
Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2
大体时间:Day 1 (single study visit)
|
In participants with COPD, the percentage of lumetry paCO2 estimates that differ by 8.0 millimeters of mercury (mmHg) or less in either direction from the paCO2 measured by capillary blood gas analysis (reference standard). |
Day 1 (single study visit)
|
|
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)
大体时间:Day 1 (single study visit)
|
In a subgroup of 50 participants with COPD, the average size of the difference, regardless of direction (mean absolute deviation), from the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for lumetry and for transcutaneous carbon dioxide monitoring (tcPCO2). The outcome is the difference between these two averages. Unit: millimeters of mercury (mmHg). |
Day 1 (single study visit)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Adverse Events, Adverse Device Effects, or Device Deficiencies
大体时间:Day 1 (single study visit)
|
Number of participants with at least one adverse event, adverse device effect, or device deficiency related to the study procedures, recorded during the study visit. |
Day 1 (single study visit)
|
|
Cross-Validated Sensitivity of a Re-Trained lumetry COPD Screening Algorithm
大体时间:Day 1 (single study visit)
|
Exploratory analysis. Sensitivity of a re-trained version of the lumetry machine learning algorithm for identifying participants with chronic obstructive pulmonary disease (COPD), estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis. |
Day 1 (single study visit)
|
|
Cross-Validated Specificity of a Re-Trained lumetry COPD Screening Algorithm
大体时间:Day 1 (single study visit)
|
Exploratory analysis. Specificity of a re-trained version of the lumetry machine learning algorithm for identifying participants without COPD, estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis. |
Day 1 (single study visit)
|
|
Cross-Validated Mean Absolute Deviation of Re-Trained lumetry paCO2 Estimates From Blood Gas paCO2
大体时间:Day 1 (single study visit)
|
Exploratory analysis. Average size of the difference, regardless of direction (mean absolute deviation), between the arterial carbon dioxide level (paCO2) estimated by a re-trained version of the lumetry machine learning algorithm and the paCO2 measured by capillary blood gas analysis, estimated by stratified repeated k-fold cross-validation in participants with COPD. Unit: millimeters of mercury (mmHg). |
Day 1 (single study visit)
|
合作者和调查者
调查人员
- 首席研究员:Arschang Valipour, Prim. Priv. -Doz. Dr.、Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine
出版物和有用的链接
一般刊物
- Klemm et al. Predicting arterial pCO2 using capnographic recordings - A pilot study using a novel breath analysis device. Eur Respir J. 2025; 66(Suppl 69): PA2529. doi:10.1183/13993003.congress-2025.PA2529
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- lumetry_03
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.